Evoke Pharma Cash on Hand 2012-2024 | EVOK

Evoke Pharma cash on hand from 2012 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Evoke Pharma Annual Cash on Hand
(Millions of US $)
2023 $5
2022 $10
2021 $9
2020 $8
2019 $6
2018 $5
2017 $8
2016 $9
2015 $9
2014 $14
2013 $24
2012 $0
2011 $1
Evoke Pharma Quarterly Cash on Hand
(Millions of US $)
2024-06-30 $9
2024-03-31 $10
2023-12-31 $5
2023-09-30 $6
2023-06-30 $7
2023-03-31 $8
2022-12-31 $10
2022-09-30 $12
2022-06-30 $13
2022-03-31 $8
2021-12-31 $9
2021-09-30 $11
2021-06-30 $17
2021-03-31 $18
2020-12-31 $8
2020-09-30 $6
2020-06-30 $8
2020-03-31 $4
2019-12-31 $6
2019-09-30 $7
2019-06-30 $7
2019-03-31 $4
2018-12-31 $5
2018-09-30 $7
2018-06-30 $7
2018-03-31 $5
2017-12-31 $8
2017-09-30 $10
2017-06-30 $13
2017-03-31 $15
2016-12-31 $9
2016-09-30 $10
2016-06-30 $4
2016-03-31 $6
2015-12-31 $9
2015-09-30 $11
2015-06-30 $10
2015-03-31 $12
2014-12-31 $14
2014-09-30 $12
2014-06-30 $16
2014-03-31 $22
2013-12-31 $24
2013-09-30 $24
2013-06-30 $1
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.005B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Teligent (TLGT) United States $0.000B 0.00